Assembly Biosciences (ASMB) Equity Average (2011 - 2026)

Assembly Biosciences' Equity Average history runs 16 years deep, the most recent figure standing at $202.7 million for Q1 2026.

• In Q1 2026, Equity Average rose 570.11% year-over-year to $202.7 million; the TTM figure through Mar 2026 stood at $202.7 million (up 570.11% YoY), while the FY2025 annual figure was $120.1 million, up 222.49% from the prior year.
• Equity Average was $202.7 million for Q1 2026 at Assembly Biosciences, up from $194.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $202.7 million in Q1 2026 to a low of $22.6 million in Q2 2025.
• Historically, Equity Average has averaged $82.9 million across 5 years, with a median of $62.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Equity Average tumbled 57.3% in 2023, then soared 570.11% in 2026.
• A 5-year view of Equity Average shows it stood at $92.5 million in 2022, then sank by 55.25% to $41.4 million in 2023, then dropped by 28.32% to $29.7 million in 2024, then surged by 556.05% to $194.7 million in 2025, then gained by 4.09% to $202.7 million in 2026.
• The last three Equity Average figures came in at $202.7 million (Q1 2026), $194.7 million (Q4 2025), and $100.4 million (Q3 2025), per Business Quant data.